Buparlisib is a selective PI3K/AKT inhibitor, which has been used in clinical trials, such as in recurrent glioblastoma, advanced breast cancer, and metastatic squamous cell carcinoma, and has significant anti-tumor effects [32,33,34]. This evidence concerns the gene AKT1 and breast cancer.